Lilly (LLY.US) officially launches Mounjaro (tirzepatide) in China, marking a significant milestone in the company's commitment to advancing healthcare solutions for patients.
AInvestThursday, Jan 2, 2025 3:30 am ET
1min read
LLY --

On January 2, 2025, Eli Lilly China announced that Mounjaro (tirzepatide injection) officially entered the Chinese market and covered two indications.Two indications:

Adults with type 2 diabetes (T2DM) who have poor blood glucose control despite diet control and exercise, and who are receiving metformin and/or sulfonylurea drugs;

Adults with initial BMI meeting the following requirements for long-term weight management: ≥28kg/m(overweight), or ≥24kg/m(obesity) and with at least one weight-related comorbidity (e.g., hypertension, abnormal lipid metabolism, hyperglycemia, obstructive sleep apnea, cardiovascular disease, etc.).

The above indications were approved by the National Medical Products Administration in May and July 2024, respectively.

There are about 148 million adult diabetes patients in China. Currently, nearly half of Chinese diabetes patients do not meet the blood glucose control target (HbA1c≥7.0%). Mounjaro can directly and indirectly act on multiple organs and tissues that cause pathological and physiological defects of T2DM, and can achieve stronger efficacy in core pathological tissues such as pancreatic β cells.

The four specifications of Mounjaro currently on the Chinese market are: 2.5mg:0.5ml, 5mg:0.5ml, 7.5mg:0.5ml, 10mg:0.5ml.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.